Opvolging na afwijkende cervixcytologie

WEYERS, S; CRIJNS, P; P, De Sutter; P, IDE; ORYE, G; POPPE, W; TJALMA, W; VERGUTS, J; WATTY, K; WUYTS, K; ..., COMMISSIE VOOR COLPOSCOPIE EN; OBSTET..., VLAAMSE VERENIGING VOOR

doi:10.2143/tvg.61.2.5002080

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the main purpose of colposcopy is to assist in the diagnosis of precancer in women with a previous cytological abnormality, it is often performed at the same time of the collection of a screening Pap smear. Colposcopy was obviously not used according to accepted guidelines [23] , [24] However, a small relative decrease was observed over time in the use of colposcopy. One colposcopy was performed per 2.9 Pap smears, in 2000, versus 3.2 Pap smears/colposcopy, in 2006.…”

Section: Discussionmentioning

confidence: 99%

“…Colposcopy was recommended in case of a first observation of high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC) or HPV-positive ASC-US, or after a second observation of atypical squamous cell of undermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) [23] , [24] . The prevalence of these lesions, estimated from a comprehensive provincial cervical cytology registry was: 0.4% for HSIL, 1.1% for LSIL, 2.2% for ASCUS and 0.1% for atypical glandular cells [25] .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Attendance at Cervical Cancer Screening and Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual Health Insurance Data (Belgium, 2002-2006)

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo assess the coverage for cervical cancer screening as well as the use of cervical cytology, colposcopy and other diagnostic and therapeutic interventions on the uterine cervix in Belgium, using individual health insurance data.MethodsThe Intermutualistic Agency compiled a database containing 14 million records from reimbursement claims for Pap smears, colposcopies, cervical biopsies and surgery, performed between 2002 and 2006. Cervical cancer screening coverage was defined as the proportion of women aged 25–64 that had a Pap smear within the last 3 years.ResultsCervical cancer screening coverage was 61% at national level, for the target population of women between 25 and 64 years old, in the period 2004–2006. Differences between the 3 regions were small, but varied more substantially between provinces. Coverage was 70% for 25–34 year old women, 67% for those aged 35–39 years, and decreased to 44% in the age group of 60–64 years. The median screening interval was 13 months. The screening coverage varied substantially by social category: 40% and 64%, in women categorised as beneficiary or not-beneficiary of increased reimbursement from social insurance, respectively. In the 3-year period 2004–2006, 3.2 million screen tests were done in the target group consisting of 2.8 million women. However, only 1.7 million women got one or more smears and 1.1 million women had no smears, corresponding to an average of 1.88 smears per woman in three years of time. Colposcopy was excessively used (number of Pap smears over colposcopies = 3.2). The proportion of women with a history of conisation or hysterectomy, before the age of 65, was 7% and 19%, respectively.ConclusionThe screening coverage increased slightly from 59% in 2000 to 61% in 2006. The screening intensity remained at a high level, and the number of cytological examinations was theoretically sufficient to cover more than the whole target population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Attendance at Cervical Cancer Screening and Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual Health Insurance Data (Belgium, 2002-2006)

et al. 2014

View full text Add to dashboard Cite

show abstract

15 Optimale afname van cellen van de baarmoederhals voor cervixscreening

2013

View full text Add to dashboard Cite

Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium

Arbyn

Benoy²,

Simoens

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Introduction: Before the introduction of vaccination against human papillomaviruses (HPV) as a new strategy of combating cervical cancer, it is required to describe the baseline prevalence of HPV infection as well as the distribution of the different HPV types in the population and among women with cervical lesions. Materials and Methods: Approximately 10,000 liquid cervical cell samples from women, resident of Flanders (North Belgium) and participating in cervical cancer screening, were assessed cytologically and virologically with a multiplex real-time PCR using primers targeting the E6/E7 genes of 16 HPV types. Correlations of HPV infection with age, geographic area, and occurrence of cytologic lesions were assessed. Results: The prevalence of cytologic abnormalities was atypical squamous cells of undetermined significance (ASC-US), 1.6%; atypical glandular cells (AGC), 0.2%; low-grade squamous intraepithelial lesion (LSIL), 2.6%; atypical squamous cells, HSIL cannot be excluded (ASC-H), 0.3%; and high-grade squamous intraepithelial lesion (HSIL), 1.2%. The frequency of high-risk HPV infections was 11% in women without cytologic abnormalities, 77% in ASC-US, 32% in AGC, 85% in LSIL, and 93% in ASC-H and HSIL. The prevalence of high-risk HPV infection was highest in

show abstract

Opvolging na afwijkende cervixcytologie

Cited by 3 publications

References 0 publications

Attendance at Cervical Cancer Screening and Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual Health Insurance Data (Belgium, 2002-2006)

Attendance at Cervical Cancer Screening and Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual Health Insurance Data (Belgium, 2002-2006)

15 Optimale afname van cellen van de baarmoederhals voor cervixscreening

Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium

Contact Info

Product

Resources

About